Mapi-Pharma Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Holding
- Established
- 2008-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.mapi-pharma.com
A Study to Asses Efficacy, Safety and Tolerability of Monthly Long-acting IM Injection of GA Depot in Subjects With RMS
Phase 3
Completed
- Conditions
- Multiple Sclerosis, Relapsing-Remitting
- Interventions
- Other: Placebo
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2023-12-01
- Lead Sponsor
- Mapi Pharma Ltd.
- Target Recruit Count
- 1016
- Registration Number
- NCT04121221
- Locations
- 🇺🇦
Mapi Pharma Research site 14, Poltava, Ukraine
🇺🇦Mapi Pharma Research site 17, Luts'k, Ukraine
🇺🇦Mapi Pharma Research site 28, Kyiv, Ukraine
Safety and Efficacy of Monthly Long-acting IM Injection of 25mg or 40 mg GA Depot in Subjects With PPMS
Phase 2
Active, not recruiting
- Conditions
- Primary Progressive Multiple Sclerosis
- Interventions
- Drug: GA Depot 40mg once monthlyDrug: GA Depot 25mg once monthly
- First Posted Date
- 2017-12-05
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Mapi Pharma Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT03362294
- Locations
- 🇮🇱
Mapi Pharma Research site 09, Haifa, Israel
🇮🇱Mapi Pharma Research site 07, Jerusalem, Israel
🇮🇱Mapi Pharma Research site 06, Rehovot, Israel
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS
Phase 1
Completed
- Conditions
- Multiple Sclerosis
- Interventions
- Drug: GA Depot 40 mgDrug: GA Depot 80 mg
- First Posted Date
- 2014-08-08
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- Mapi Pharma Ltd.
- Target Recruit Count
- 25
- Registration Number
- NCT02212886
- Locations
- 🇮🇱
Rambam Medical Center, Haifa, Israel
🇮🇱TASMC, Tel Aviv, Israel
🇮🇱Barzilai Medical Center, Ashkelon, Israel
© Copyright 2025. All Rights Reserved by MedPath